Caricamento...
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis
Dalfampridine sustained-release (SR) is a time-release formulation of 4-aminopyridine, recently approved by the Food and Drug Administration to improve walking in patients with multiple sclerosis (MS). In Phase II trials, walking speed and lower extremity muscle strength was increased in patients wi...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2010
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3065554/ https://ncbi.nlm.nih.gov/pubmed/21468366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CE.S9046 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|